Hologic, Inc. vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
6.1
Neutral
Overall
6.7
Neutral
Quality
Health
Growth
Valuation
Sentiment
HOLX
Clean balance sheet with low leverage (0.5× debt-to-equity).
⚠ cautious analyst consensus — few Buy ratings.
MRK
Forward P/E of 11.5× is low relative to sector peers.
Analyst Consensus
HOLD
Target $76.67 (+0.9%)
9 analysts
BUY
Target $129.74 (+15.7%)
27 analysts
Fundamentals
HOLX
MRK
31.5×
Trailing P/E
31.5×
15.6×
Forward P/E
11.5×
13.2%
Profit Margin
13.6%
60.4%
Gross Margin
76.6%
10.9%
ROE
—
2.5%
Revenue Growth
4.9%
-9.2%
Earnings Growth
—
0.70
Beta
0.28
—
Price / Book
—
$17.0B
Market Cap
$277.0B
$52 – $76
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →